VASP and type 2 diabetes mellitus: Significantly better inhibition of ADP signaling pathway in prasugrel-treated T2D patients was demonstrated with significantly lower PRI of VASP-P in both samples (sample 1: 46.8 ± 33.5 versus 78.3 ± 13.0, p < 0.05; sample 2: 18.7 ± 15.7 versus 56.8 ± 18.7, p < 0.01).